A 24‐Week Anemia Correction Study of Daprodustat in Japanese Dialysis Patients

Daprodustat is an oral hypoxia‐inducible factor prolyl hydroxylase inhibitor developed for treating anemia of chronic kidney disease. This 24‐week, phase 3, open‐label study (NCT02829320) evaluated whether daprodustat could achieve and maintain target hemoglobin levels in Japanese hemodialysis patie...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Therapeutic apheresis and dialysis 2020-04, Vol.24 (2), p.108-114
Hauptverfasser:	Tsubakihara, Yoshiharu, Akizawa, Tadao, Nangaku, Masaomi, Onoue, Tomohiro, Yonekawa, Taeko, Matsushita, Hideki, Endo, Yukihiro, Cobitz, Alexander
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Anemia Anemia - drug therapy Anemia - etiology Barbiturates - adverse effects Barbiturates - therapeutic use Chronic kidney disease Daprodustat Dialysis Female Glycine - adverse effects Glycine - analogs & derivatives Glycine - therapeutic use Hemoglobins - analysis Humans Hypoxia-Inducible Factor-Proline Dioxygenases - antagonists & inhibitors Japan Japanese Male Middle Aged Renal Dialysis Renal Insufficiency, Chronic - complications Renal Insufficiency, Chronic - therapy Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!